| Document And Entity Information | 12 Months Ended |
| Dec. 31, 2023 shares | |
| Document Information Line Items | |
| Entity Registrant Name | ALTAMIRA THERAPEUTICS LTD. |
| Trading Symbol | CYTO |
| Document Type | 20-F/A |
| Current Fiscal Year End Date | --12-31 |
| Entity Common Stock, Shares Outstanding | 1,477,785 |
| Amendment Flag | true |
| Amendment Description | Altamira Therapeutics Ltd. (the “Company”) is filing this Amendment No. 2 (“Amendment No. 2”) to the Annual Report on Form 20-F for the year ended December 31, 2023 (the “2023 Form 20-F”), as filed with the United States Securities and Exchange Commission (the “SEC”) on April 10, 2024 (the “Original Filing Date”), as amended on April 22, 2024, solely to supplement “Item 18: Financial Statements” and “Item 19: Exhibits” of the 2023 Form 20-F with the inclusion of the audited financial statements of Altamira Medica AG (the “Medica Financial Statements”), including the report of BDO AG, an independent registered public accounting firm, relating thereto as required under Rule 3-09 of Regulation S-X.Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, this Amendment No. 2 also includes, as Exhibits 12.1, 12.2, 13.1 and 13.2, the certifications of the Principal Executive Officer and Principal Financial Officer of the Company pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of 2002. This Amendment No. 2 also includes Exhibit 15.3, which contains the consent of BDO AG, an independent registered public accounting firm, with respect to their report included in the Medica Financial Statements.Except as described above, no changes have been made to the 2023 Form 20-F, and this Amendment No. 2 does not modify, amend or update the financial or other information contained in the 2023 Form 20-F. This Amendment No. 2 does not reflect any events that have occurred on or after the Original Filing Date. Among other things, the Company has not revised forward-looking statements made in the 2023 Form 20-F to reflect events that occurred or facts that became known to the Company after the Original Filing Date. Therefore, this Amendment No. 2 should be read in conjunction with the 2023 Form 20-F and any other documents that the Company has filed with the SEC on or after the Original Filing Date. |
| Entity Central Index Key | 0001601936 |
| Entity Current Reporting Status | Yes |
| Entity Voluntary Filers | No |
| Entity Filer Category | Non-accelerated Filer |
| Entity Well-known Seasoned Issuer | No |
| Document Period End Date | Dec. 31, 2023 |
| Document Fiscal Year Focus | 2023 |
| Document Fiscal Period Focus | FY |
| Entity Emerging Growth Company | false |
| Entity Shell Company | false |
| ICFR Auditor Attestation Flag | false |
| Document Registration Statement | false |
| Document Annual Report | true |
| Document Transition Report | false |
| Document Shell Company Report | false |
| Entity File Number | 001-36582 |
| Entity Incorporation, State or Country Code | D0 |
| Entity Address, Address Line One | Clarendon House |
| Entity Address, Address Line Two | 2 Church Street |
| Entity Address, City or Town | Hamilton |
| Entity Address, Postal Zip Code | HM11 |
| Entity Address, Country | BM |
| Title of 12(b) Security | Common Shares, par value USD 0.002 per share |
| Security Exchange Name | NASDAQ |
| Entity Interactive Data Current | Yes |
| Document Financial Statement Error Correction [Flag] | false |
| Document Accounting Standard | International Financial Reporting Standards |
| Auditor Firm ID | 5988 |
| Auditor Name | BDO AG |
| Auditor Location | Schiffbaustrasse 2 8031 Zürich |
| Business Contact | |
| Document Information Line Items | |
| Entity Address, Address Line One | Clarendon House |
| Entity Address, Address Line Two | 2 Church Street |
| Entity Address, City or Town | Hamilton |
| Entity Address, Postal Zip Code | HM11 |
| Entity Address, Country | BM |
| Contact Personnel Name | Thomas Meyer |
| City Area Code | +1 (441) |
| Local Phone Number | 295 59 50 |
